Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer

BACKGROUND: National Comprehensive Cancer Network guidelines recommend monthly osteoclast inhibitor treatment (OIT) in men with metastatic castration-resistant prostate cancer (mCRPC) to prevent skeletal related events (SREs). We assessed adherence to guidelines by quantifying treatment for SRE prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonnenburg, Daniel, Chaudhuri, Parul, Graves, Amy J., Penson, David F., Morgans, Alicia K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457685/
https://www.ncbi.nlm.nih.gov/pubmed/30984916
http://dx.doi.org/10.31487/j.COR.2018.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457685/
https://www.ncbi.nlm.nih.gov/pubmed/30984916
http://dx.doi.org/10.31487/j.COR.2018.03.001

Ejemplares similares